Literature DB >> 24293411

Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer.

Zi Liu1, Liang Ma, Zhe-Sheng Wen, Zheng Hu, Fu-Qun Wu, Wei Li, Jinsong Liu, Guang-Biao Zhou.   

Abstract

Celastrol binds CIP2A and enhances CIP2A-CHIP interaction, leading to ubiquitination/degradation of CIP2A and inhibition of lung cancer cells in vitro and in vivo. Celastrol potentiates cisplatin's efficacy by suppressing the CIP2A-Akt pathway, and therefore CIP2A inhibitors may represent novel therapeutics for cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24293411      PMCID： PMC4319067          DOI： 10.1093/carcin/bgt395

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN： 0143-3334            Impact factor:   4.944


  52 in total

Review 1.  Proteolysis: from the lysosome to ubiquitin and the proteasome.

Authors:  Aaron Ciechanover
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

2.  The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation.

Authors:  Claudia Esser; Martin Scheffner; Jörg Höhfeld
Journal:  J Biol Chem       Date:  2005-05-23       Impact factor: 5.157

3.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

Authors:  Haley Hieronymus; Justin Lamb; Kenneth N Ross; Xiao P Peng; Cristina Clement; Anna Rodina; Maria Nieto; Jinyan Du; Kimberly Stegmaier; Srilakshmi M Raj; Katherine N Maloney; Jon Clardy; William C Hahn; Gabriela Chiosis; Todd R Golub
Journal:  Cancer Cell       Date:  2006-09-28       Impact factor: 31.743

Review 4.  Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis.

Authors:  Steven M Harwood; Muhammad M Yaqoob; David A Allen
Journal:  Ann Clin Biochem       Date:  2005-11       Impact factor: 2.057

5.  Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.

Authors:  Guang-Biao Zhou; Hui Kang; Lan Wang; Li Gao; Ping Liu; Jun Xie; Feng-Xiang Zhang; Xiang-Qin Weng; Zhi-Xiang Shen; Jue Chen; Long-Jun Gu; Ming Yan; Dong-Er Zhang; Sai-Juan Chen; Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

Review 6.  Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer.

Authors:  Ceshi Chen; Arun K Seth; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2006-10       Impact factor: 5.852

7.  Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions.

Authors:  C A Ballinger; P Connell; Y Wu; Z Hu; L J Thompson; L Y Yin; C Patterson
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

8.  Structural bioinformatics-based design of selective, irreversible kinase inhibitors.

Authors:  Michael S Cohen; Chao Zhang; Kevan M Shokat; Jack Taunton
Journal:  Science       Date:  2005-05-27       Impact factor: 47.728

9.  Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice.

Authors:  Huanjie Yang; Di Chen; Qiuzhi Cindy Cui; Xiao Yuan; Q Ping Dou
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

10.  AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.

Authors:  Ling-Zhi Liu; Xiang-Dong Zhou; Guisheng Qian; Xianglin Shi; Jing Fang; Bing-Hua Jiang
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701
View more
  36 in total

1.  Development of EBV-encoded small RNA targeted PCR to classify EBV positive diffuse large B-cell lymphoma (DLBCL) of the elderly.

Authors:  Jaewang Lee; Min Park; Min Ho Lee; Hyun Jun Woo; Hyun-Woo Kim; Ji Yeong Yang; Yong-Bin Eom; Sa-Hyun Kim; Changyoung Yoo; Jong-Bae Kim
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

2.  Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.

Authors:  Hui Wei; Hui-Liang Zhang; Jia-Zhao Xie; Dong-Li Meng; Xiao-Chuan Wang; Dan Ke; Ji Zeng; Rong Liu
Journal:  Curr Med Sci       Date:  2020-03-13

3.  Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site.

Authors:  Yi-Liang Liu; Steffen Lindert; Wei Zhu; Ke Wang; J Andrew McCammon; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

4.  Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells.

Authors:  Zi Liu; Liang Ma; Zhe-Sheng Wen; Yong-Xian Cheng; Guang-Biao Zhou
Journal:  ACS Med Chem Lett       Date:  2013-12-20       Impact factor: 4.345

5.  Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.

Authors:  Shan Li; Ting-Ting Feng; Yang Guo; Xianjun Yu; Qiuyue Huang; Liang Zhang; Wei Tang; Ying Liu
Journal:  Oncol Lett       Date:  2016-11-09       Impact factor: 2.967

Review 6.  Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.

Authors:  Godfrey Grech; Shawn Baldacchino; Christian Saliba; Maria Pia Grixti; Robert Gauci; Vanessa Petroni; Anthony G Fenech; Christian Scerri
Journal:  Tumour Biol       Date:  2016-07-21

7.  A lipidomics investigation into the intervention of celastrol in experimental colitis.

Authors:  Renping Wang; Xueqin Gu; Weiquan Dai; Jun Ye; Feng Lu; Yifeng Chai; Guorong Fan; Frank J Gonzalez; Gengli Duan; Yunpeng Qi
Journal:  Mol Biosyst       Date:  2016-04-26

Review 8.  Therapeutic targeting of PP2A.

Authors:  Caitlin M O'Connor; Abbey Perl; Daniel Leonard; Jaya Sangodkar; Goutham Narla
Journal:  Int J Biochem Cell Biol       Date:  2017-10-26       Impact factor: 5.085

Review 9.  All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Authors:  Jaya Sangodkar; Caroline C Farrington; Kimberly McClinch; Matthew D Galsky; David B Kastrinsky; Goutham Narla
Journal:  FEBS J       Date:  2015-11-14       Impact factor: 5.542

10.  Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells.

Authors:  Hong Yu; Hong-Ying Gao; Hua Guo; Gui-Zhen Wang; Yi-Qing Yang; Qian Hu; Li-Jun Liang; Qun Zhao; Da-Wei Xie; Yu Rao; Guang-Biao Zhou
Journal:  Acta Pharmacol Sin       Date:  2021-05-25       Impact factor: 6.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.